Pharmacology of vecuronium in patients with end-stage renal failure.
Vecuronium was administered as an intravenous bolus (50 micrograms kg-1) to 10 normal and 10 anephric patients. The elimination half-life was 50.7 +/- 20.3 min in normal patients and 67.826.3 min in anephric patients. The plasma clearance was 3.6 +/- 1.5 ml min-1 for normal patients and 4.5 +/- 2.6 ml min-1 kg-1 for anephric patients. Only the volume of the second compartment was statistically increased (+90%, P less than 0.05) in anephric patients. The duration of action in normal patients (25.3 +/- 9.8 min) was comparable to the duration of action in patients with renal failure (32.8 +/- 10.7 min), but the recovery index was prolonged (+45%, P less than 0.05) in anephric patients.
D000328:Adult; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000503:physiopathology*; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D013997:Time Factors; D014673:Vecuronium Bromide / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*
D014673:Vecuronium Bromide